Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 19:7:1025-32.
doi: 10.2147/OTT.S40527. eCollection 2014.

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Chiara Della Pepa  1 , Susana Banerjee  1
Affiliations
Review

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer

Chiara Della Pepa et al. Onco Targets Ther. .

Erratum in

  • Onco Targets Ther. 2014;7:1473

Abstract

Targeting angiogenesis is proving to be a successful approach in the management of ovarian cancer. The vascular endothelial growth factor inhibitor, bevacizumab, is the first angiogenesis inhibitor to have shown a significant progression-free survival advantage in the Phase III setting. There is now evidence supporting the use of bevacizumab in combination with chemotherapy for first-line and relapsed (platinum-sensitive and resistant) ovarian cancer. In this review, we summarize the positive Phase III trial (OCEANS [Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease]) that led to European Medicines Agency approval of bevacizumab in platinum-sensitive first relapse and discuss the best use of the drug in this disease.

Keywords: antiangiogenic; ovarian; recurrent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
OCEANS study. Note: *Up to ten cycles in case of ongoing response. Abbreviations: BV, bevacizumab 15 mg/m2; CI, confidence interval; CG, carboplatin AUC 4 (area under the curve), gemcitabine 1,000 mg/m2; GIP, gastrointestinal perforation; HR, hazard ratio; ORR, overall response rate; PD, progression disease; PFS, progression-free survival; Pl, placebo; PS, Eastern Cooperative Oncology Group Performance Status; pts, patients; vs, versus; OCEANS, Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-aging Therapy in Platinum-Sensitive Recurrent Disease.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. - PubMed
    1. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group EUROCARE-4. Survival of cancer patients diagnosed in1995–1999. Results and commentary. Eur J Cancer. 2009;45(6):931–991. - PubMed
    1. Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62(1):59–70. - PubMed
    1. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961–968. - PubMed
    1. Colombo N, Peiretti M, Parma G, et al. ESMO Guidelines Working Group Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v23–v30. - PubMed

LinkOut - more resources